Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL)
Status:
Completed
Trial end date:
2011-02-26
Target enrollment:
Participant gender:
Summary
This is a Phase I/II study of a drug called bortezomib given in combination with chemotherapy
drugs used to treat acute lymphoblastic leukemia (ALL) that has come back (recurred).
Bortezomib is a drug that has been approved by the Food and Drug Administration (FDA) for
treating adults with multiple myeloma which is a type of blood cancer. Bortezomib has been
shown to cause cancer cells to die in studies done on animals (mice). Studies have been done
that have shown that some adults and children with cancer have shown a response to bortezomib
when it is used alone. Studies have also been done in adults to evaluate the dose of
bortezomib that can be safely given in combination with other chemotherapy drugs.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Therapeutic Advances in Childhood Leukemia Consortium